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Abstract
Although B. bronchiseptica efficiently infects a wide range of mammalian hosts and efficiently spreads among them, it is
rarely observed in humans. In contrast to the many other hosts of B. bronchiseptica, humans are host to the apparently
specialized pathogen B. pertussis, the great majority having immunity due to vaccination, infection or both. Here we explore
whether immunity to B. pertussis protects against B. bronchiseptica infection. In a murine model, either infection or
vaccination with B. pertussis induced antibodies that recognized antigens of B. bronchiseptica and protected the lower
respiratory tract of mice against three phylogenetically disparate strains of B. bronchiseptica that efficiently infect naı ¨ve
animals. Furthermore, vaccination with purified B. pertussis-derived pertactin, filamentous hemagglutinin or the human
acellular vaccine, Adacel, conferred similar protection against B. bronchiseptica challenge. These data indicate that individual
immunity to B. pertussis affects B. bronchiseptica infection, and suggest that the high levels of herd immunity against B.
pertussis in humans could explain the lack of observed B. bronchiseptica transmission. This could also explain the apparent
association of B. bronchiseptica infections with an immunocompromised state.
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Introduction
The emergence of new infectious diseases from zoonotic sources
may be constrained by at least three limiting steps. First, a
pathogen must have the opportunity, observed when organisms
‘‘spillover’’ from their natural host to humans. Second, it must
have the ability to colonize/infect an individual and to expand in
numbers there. Third, it must successfully spread to new human
hosts and establish a successful chain of transmission [1,2]. It is
important to consider the factors that can affect each of these steps
in order to understand the risk of newly emerging diseases.
Successful transmission requires shedding of the pathogen from an
infected individual and contact with susceptible individuals. In the
simplest case of a novel infectious agent, all of a new host
population are often considered to be susceptible until they are
infected, recover and may then be immune, at least for a time.
However, the susceptibility of individual hosts to a novel agent
may be affected by various factors, including the resident flora and
immunity to it. Since pathogen control strategies such as
vaccination can change the immune status of individuals, and
the human population, it is important to understand how that
might affect their susceptibility to not just that pathogen, but to
other closely related pathogens that are likely to spillover from
animal sources.
The classical bordetellae are closely related gram-negative
bacterial species which colonize the respiratory tracts of a variety
of mammalian hosts [3]. Bordetella bronchiseptica causes a chronic
respiratory infection that can persist for the life of the animal [3,4].
This pathogen has been isolated from a diverse range of
mammalian hosts and is associated with kennel cough in dogs,
snuffles in rabbits and atrophic rhinitis in pigs but may be present
without symptoms in a majority of these and other animals [3–5].
The individual lineages of B. bronchiseptica do not appear to be host-
specific, since very closely related strains have been shown to
efficiently infect a wide range of mammals, including humans [5–
16]. Although dogs and other animals are common hosts for a
wide variety of lineages of B. bronchiseptica, one specialized lineage
of Bordetella has adapted to occupy humans as its only apparent
ecological niche; B. pertussis is prevalent worldwide as a highly
infectious pathogen that causes the acute disease whooping cough
[3]. Although infections are cleared by host immunity, B. pertussis
persists within human populations by reinfecting previously
infected or vaccinated individuals [3,17]. We have suggested that
the very high prevalence of antibodies to B. pertussis, detectable in
greater than 90% of individuals, may reflect immunity that affects
the emergence of closely related pathogens [17].
Other classical bordetellae retain the ability to infect humans, but
only B. parapertussis appears to successfully occupy humans as a
primary ecological niche [3,18]. Since immune-mediated competi-
tion would be expected to exclude one or the other from a shared
host population, we hypothesized, and recently showed, that B.
parapertussisavoidscross-immunityviathe expressionofan O-antigen
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induced by the latter to shared antigens on the bacterial surface
[13,15,19–21].This appears to have allowed B.parapertussis to invade
a human population in which B. pertussis was already endemic.
Animals in very close contact with humans, such as dogs and
cats, are known to be infected with a very wide range of different
B. bronchiseptica strains, which are highly infectious and spread
amongst them rapidly. Interestingly, a similarly broad set of B.
bronchiseptica strains have been occasionally isolated from humans,
indicating they retain the ability to infect humans, but they
generally are not observed to spread between humans [5,12]. The
observations that B. bronchiseptica can spillover to humans from
animals, and can infect and cause disease, particularly in
immunocompromised individuals, led us to explore how the
infectious process may be affected by immunity to the resident
pathogen, B. pertussis.
Here we quantified the effects of B. pertussis-induced immunity
on the ability of B. bronchiseptica to successfully infect mice [22–24].
We show that B. pertussis infection- and vaccine-induced immunity
protects against B. bronchiseptica colonization in the lower
respiratory tract (LRT). This protection, defined as a significant
decrease in bacterial load in the LRT of an immunized host,
appears to be mediated by cross reacting antibodies which
recognize shared antigens. Immunization with the B. pertussis-
derived antigens in the acellular vaccine, Adacel, or the individual
proteins pertactin or filamentous hemagglutinin, was sufficient to
induce protective immunity to B. bronchiseptica. Thus B. pertussis
vaccination- or infection-induced immunity can protect the LRT
of mice against B. bronchiseptica. Together with our previous
demonstration that B. parapertussis avoids B. pertussis-induced
immunity, these data may explain, in whole or in part, why B.
bronchiseptica is observed to spillover to humans from other animals
in which it causes epidemics, but is generally associated with
disease only in immunocompromised humans.
Materials and Methods
Bacterial Growth
Bordetella pertussis strain 536, a streptomycin resistant derivative
of Tohama I [25], B. bronchiseptica strain RB50 [26], and B.
bronchiseptica strain RB50G, a gentamicin-resistant derivative of
RB50 [27], have been previously described. Human isolates of B.
bronchiseptica, strains A345 (a.k.a. B2493 and GA96-01) and M0149
(a.k.a. D444 and B2494), were received from the CDC and multi-
locus sequence typed as previously described [5]. All strains were
maintained on Bordet-Gengou (BG) Agar (Difco, Sparks, MD)
with 10% sheep’s blood (Hema Resources, Aurora, OR) with
20 mg/ml of streptomycin or gentamicin. Bacteria were grown
overnight at 37uC in Stainer-Scholte broth [28–30] to mid-
exponential phase and diluted in phosphate buffered saline (PBS,
Omnipur, Gibbstown, NJ) to the indicated concentration.
Animal Care and Housing
4 to 6 week old C57BL/6, mMT and RAG2
2/2 mice were
obtained from Jackson Laboratories (Bar Harbor, ME). IgA
2/2
mice were obtained from Dr. Innocent Mbawuike [31]. C3
2/2
mice were obtained from Dr. Rick Wetsel [32]. Mice lacking Fcc
Receptor I, II, and III (FccR
2/2) were obtained from Taconic
(Hudson, NY). All mice were maintained and bred in Pennsylva-
nia State University approved housing facilities and were closely
monitored in accordance with institutional policies and the
Institutional Animal Care and Use Committee (IACUC) regula-
tions (IACUC approval number for breeding: 31180 and for
experiments: 31297).
Inoculation and Vaccination of Mice
For inoculation, mice were lightly sedated by a flow of 5%
isoflurane in oxygen and a 50 ml inoculum containing 5610
5 CFU
was pipetted gently onto the external nares. This method of
inhalation inoculation reliably distributes the bacteria throughout
the respiratory tract [22]. For vaccination, the mice were
intraperitoneally (i.p.) injected with 1610
8 heat killed B. pertussis
in 1 ml of PBS [33], 40 mg of purified pertactin 1 [34] or 5 mgo f
filamentous hemagglutinin (Sigma, St. Louis, MO) in 200 mLo f
PBS with Imject Alum (Pierce, Rockford, IL), or subcutaneously
injected with 0.5 ml of 1:5 dilution of the 5-component human
vaccine, Adacel (aP) (Sanofi-Pasteur, Swiftwater, PA) in PBS with
Imject Alum on Day 0 and Day 14. Mice were euthanized by CO2
inhalation and nasal cavities, trachea and lungs were excised,
homogenized and serially diluted in PBS. Aliquots were then
plated on BG Agar with appropriate antibiotics and the resultant
colonies were counted two days later.
Antibiotic Treatment and Depletion of Immune Factors
For all reinfection experiments, 1% gentamicin (Sigma, St.
Louis, MO) was administered in the drinking water for 3 days
beginning on day 23 post-B. pertussis inoculation [35]. Mice were
then given untreated water for 2 days prior to challenge with
RB50G. Previous studies have shown that gentimicin treatment
does not hinder B. bronchiseptica strain RB50G colonization of the
murine respiratory tract [35]. Neutrophils were depleted by i.p.
injection of 1 mg of mAb from the hybridoma RB6-8C5 (aLy-6G)
48 hours prior to bacterial inoculation [33]. Depletion of 95% of
blood neutrophils was confirmed via CBC differential count.
Complement was depleted by two i.p. injections of 5 units of
Cobra Venom Factor (CVF, Sigma, St. Louis, MO) 24 and
22 hours prior to inoculation [36].
Generation and Passive Transfer of Immune Serum
Convalescent mice were generated by inoculating mice with the
indicated bacteria and allowing themiceto recover for 28 days [33].
Pooled serum was collected via post-mortem cardiac puncture from
wild type convalescent or naive mice. To induce a higher titer of B.
pertussis-specific antibodies, B. pertussis-inoculated mice were allowed
to convalesce for 28 days followed by a second challenge with B.
pertussis and subsequent cardiac puncture 3 days post secondary
inoculation. To generate complement deficient serum, sera were
heat-inactivated at 65uC for 30 minutes prior to passive transfer.
Passive transfer experiments used 200 mL of serum i.p. injected at
the time of inoculation [23,33].
Western Blots Analysis
Westerns Blots were performed on lysates of 1610
6 CFU of B.
pertussis, or B. bronchiseptica in 10 mL Laemmli sample buffer (Bio-
Rad, Hercules, CA). Lysates were run on 7%SDS-PAGEgelsunder
denaturing conditions and then transferred to PVDF membranes.
The membraneswere then probed overnight witha 1:100 dilutionof
serum collected from a naı ¨ve mouse or a mouse inoculated with a
single dose of B. pertussis for 28 days (5610
5 CFU in 50 ul) and a
1:10,000 dilution of goat anti-mouse Ig (H+L) HRP-conjugated
(Southern Biotech, Birmingham, AL) was used as the detector
antibody. The membrane was visualized with ECL Western Blotting
detection reagents (Amersham Biosciences, Piscataway, NJ).
Statistical Analysis
Student’s two-tailed t-test was used to determine statistical
significance between experimental groups. P-values of#0.05 were
considered significant. Error bars represent SEM.
Bordetella Cross Immunity
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Immunity to B. pertussis protects against B. bronchiseptica
challenge in the LRT
To test the hypothesis that B. pertussis-induced immunity protects
against B. bronchiseptica colonization of the LRT, wild type mice were
inoculated with live B. pertussis or vaccinated with heat-killed B.
pertussis and allowed to recover for at least 28 days. By this time
point, bacterial numbers in the respiratory tract were reduced to
approximately 10
2 or fewer CFU and a strong immune response
had been induced [23]. B. pertussis-vaccinated, -previously infected,
ornaı ¨vemicewere gentamicin treatedtoclearanyremnantbacteria
and then challenged with a gentamicin resistant strain of B.
bronchiseptica and the bacterial load was enumerated on Days 3, 7, 10
and 14 post-challenge. Approximately 10
4 CFU in the trachea and
10
6 CFU in the lungs were recovered on both Days 3 and 7 post-
challenge in naı ¨ve mice (Figure 1). However, only approximately
1% (10
2 CFU) and 0.05% (10
3 CFU) B. bronchiseptica were recovered
from the trachea and lungs by Day 3 post-challenge in immunized
mice as compared to naı ¨ve animals (Figure 1). By Day 7 post-
challenge, previously infected mice retained approximately 10
2
CFU of B. bronchiseptica in the trachea, and 10
3 CFU of B.
bronchiseptica in the lungs, and carried these low loads of B.
bronchiseptica for approximately 2 weeks, until bacteria were
undetectable on Day 14 post-challenge. Vaccinated mice cleared
B.bronchisepticafromthetracheaand lungsbyDay7post-inoculation
(Figure 1). These data support the hypothesis that immunity to B.
pertussis protects against a B. bronchiseptica challenge in the LRT. In
the nasal cavities, B. pertussis immunized mice have similar
colonization kinetics to naı ¨ve mice (Figure 1). Although immunity
to B. pertussis has limited effects on B. bronchiseptica colonization in the
nasal cavity, the rapid and significant reduction of B. bronchiseptica
numbers in the LRT of B. pertussis immunized hosts minimized the
inflammation and pathology which would have further led to
disease symptoms and transmission. Because a very large and
significant effect of prior exposure to B. pertussis on the colonization
of B. bronchiseptica was observed on Day 3 post-challenge, subsequent
experiments were carried out at this timepoint.
B. pertussis-induced immunity requires B cells, but not
IgA, for protection against B. bronchiseptica challenge in
the lungs
Since immunization with B. pertussis led to protection against B.
bronchiseptica, we sought to determine if this was mediated by the
adaptive immune response. B. pertussis-immunized RAG
2/2 mice
were unable to reduce B. bronchiseptica numbers, indicating a role
for adaptive immunity in protection (data not shown). We
hypothesized that B. pertussis-induced antibodies could recognize
B. bronchiseptica antigens and mediate the clearance of this
pathogen. Supporting this hypothesis, there was no difference in
bacterial load in the trachea or the lungs between immunized or
naı ¨ve mMT mice on Day 3 post B. bronchiseptica challenge (Figure 2).
These data indicate that B cells, and the antibodies they produce
[23], are required for cross protection.
We further hypothesized that the major mucosal antibody, IgA,
would be the primary protective antibody [35]. IgA
2/2 mice were
vaccinated or infected with B. pertussis and allowed to convalesce for
28 days. The treated or naı ¨ve mice were then challenged with B.
bronchisepticaand dissected Day 3 post-inoculation. The bacterialload
inthelungsofnaı ¨veIgA
2/2micewasnotsignificantlydifferentfrom
naive wild type mice (Figure 2). Consistent with previous findings,
immunized IgA
2/2 mice were not protected against B. bronchiseptica
challenge in the trachea [35]. Immunization reduced B. bronchiseptica
numbers in the lungs of IgA2/2 mice by greater than 95%,
although immunization reduced bacterial numbers by .99.9% in
wild type mice, relative to naı ¨ve mice. Thus, IgA is required for B.
pertussis-immune-mediated protection against B. bronchiseptica in the
trachea, but is not as important in the lungs.
B. pertussis-induced sera require complement and
neutrophils to reduce B. bronchiseptica colonization
To determine if B. pertussis-induced sera can clear B. bronchiseptica
upon passive transfer into naı ¨ve mice, wild type mice were
Figure 1. B. bronchiseptica numbers in the respiratory tract of
naı ¨ve and B. pertussis immune mice over time. Groups of 3 to 4
C57BL/6 mice were left uninoculated (¤), inoculated with 5610
5 CFU of
B. pertussis (&), or vaccinated with 2 i.p. injections of 10
8 heat killed B.
pertussis on Days 0 and 14 (m). On Day 21, mice were gentimicin-
treated for 3 days. Mice were then challenged with a gentimicin
R strain
of B. bronchiseptica on Day 28 and sacrificed at the indicated day post-
challenge for quantification of bacterial load in nasal cavity (A), trachea
(B) and the lungs (C). Bacterial numbers are represented as the mean
Log10 CFU+/2SEM. Dashed line represents the lower limit of detection.
* indicates statistical difference (P value,0.05) between naı ¨ve and
treated groups.
doi:10.1371/journal.pone.0006778.g001
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200 mLo fn a ı ¨ve, B. bronchiseptica- or B. pertussis-induced immune
serum. The mice were then dissected on Day 3 post-inoculation for
bacterial enumeration. Compared to untreated mice, naı ¨ve serum
had no effect on bacterial numbers (Figure 3A). In contrast, B.
pertussis-immune serum (titer ,400) reduced bacterial numbers in
the lungs and trachea by greater than 85% (Figure 3A). B. pertussis-
immune serum with a titer of 6400, a titer similar to that of B.
bronchiseptica-induced immune serum, reduced B. bronchiseptica
numbers in both organs by.99.9% relative to that of naı ¨ve serum
treated mice, an effect similar to that of B. bronchiseptica-immune
serum (Figure 3A). Together, these data suggest that B. pertussis-
inducedseraareabletoefficientlyreducenumbersofB.bronchiseptica
in the LRT in a dose-dependent manner. Naı ¨ve serum, while
containing other components such as albumin and complement,
had no effect on bacterial numbers, suggesting B. pertusis-specific
antibodies mediate the reduction of B. bronchiseptica colonization.
Our previous work showed that antibodies induced by B.
bronchiseptica infection clear this bacterium from the lungs of mice
via a complement and neutrophil-dependent mechanism [37,38].
Thus, we hypothesized that B. pertussis-induced antibodies would
also required the complement cascade and/or neutrophils in order
to clear B. bronchiseptica. To test this hypothesis, mice were CVF
treated to deplete complement or were treated with aLy-6G
monoclonal antibody to deplete neutrophils prior to inoculation
with B. bronchiseptica. While B. pertussis-immune serum reduced B.
bronchiseptica numbers in untreated mice, it did not significantly
reduce bacterial numbers in the lungs of CVF or aLy-6G treated
mice, indicating that both complement and neutrophils are
required (Figure 3B). In addition, all aLy-6G treated mice were
moribund by Day 2 post-inoculation, indicating that B. pertussis-
specific sera did not protect against the rapid virulence of B.
bronchiseptica in animals lacking neutrophils.
To determine if complement and Fcc Receptors are required for
B. pertussis-immunization induced protection of the LRT against B.
bronchiseptica,C 3
2/2 mice, which lack the enzyme required for both
the classical and the alternative complement cascades, and FccR
2/2
mice, which lack Fcc Receptors (I, II, and III) specific for the Fc
region of IgG antibodies, were immunized with B. pertussis and then
challenged 28 days later with B. bronchiseptica.I nb o t hC 3
2/2 and
FccR
2/2 mice that were previously vaccinated or infected with B.
pertussis,t h eB. bronchiseptica bacterial load in the lungs was
significantly decreased by Day 3 post-inoculation when compared
to naı ¨ve mice (Figure 4), indicating that either vaccination or
Figure 2. B. bronchiseptica numbers in the LRT of immunized B-
cell and IgA deficient mice. Naı ¨ve (black bars), B. pertussis-vaccinated
(white bars), or B. pertussis-convalescent (hatched bars) C57BL/6, mMT
and IgA
2/2 mice were dissected Day 3 post gentimicin
R B. bronchi-
septica challenge. Bacterial numbers in the trachea (A) and lungs (B) are
represented as the mean Log10 CFU+/2SEM. Dashed line indicates the
lower limit of detection. * indicates statistical difference (P value,0.05)
between naı ¨ve and treated groups. { indicates statistical difference (P
value,0.05) between mutant mouse and similarly treated wild type
mouse groups.
doi:10.1371/journal.pone.0006778.g002
Figure 3. Effect of Complement and Neutrophils on B. pertussis
serum antibody-mediated clearance of B. bronchiseptica. (A) Wild
type mice infected with B. bronchiseptica were untreated (black bars) or
i.p. injected with naı ¨ve serum (white bars), B. bronchiseptica-immune
serum (hatched bars), B. pertussis-immune serum titer 400 (gray bars), or
B. pertussis-immune serum titer 6400 (horizontal lined bars) and then
dissected Day 3 post-inoculation. (B) Wild type mice were complement
(CVF) or neutrophil (aLy-6G) depleted, then inoculated with B.
bronchiseptica, i.p. injected with the indicated serum and then dissected
on Day 2 post-inoculation. B.b. indicates B. bronchiseptica-immune
serum; B.p. indicates B. pertussis-immune serum titer 6400. Bacterial
numbers are represented as the mean Log10 CFU+/2SEM. Dashed line
indicates the lower limit of detection. * indicates P value of ,0.05.
doi:10.1371/journal.pone.0006778.g003
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In the trachea, B. pertussis immunization reduced bacterial numbers
significantly in FccR
2/2 mice, but not significantly in C3
2/2 mice,
relative to naı ¨vemice(Figure 4). Together theseresults are consistent
withourpreviousfindingsthatadoptivelytransferredimmuneserum
conferred protection against B. bronchiseptica that was dependent on
both complement and FccRs (Figure 3)[33], but infection-induced
protection was much less dependent on either (Figure 4)[39].
B. pertussis-induced sera recognize antigens on B.
bronchiseptica
Since passive immunization with B. pertussis-induced sera can
control B. bronchiseptica infection in the LRT, we examined
recognition of B. bronchiseptica antigens by B. pertussis-infection-
induced serum. Western Blot analysis of B. pertussis and B.
bronchiseptica lysates probed with B. pertussis-infection-induced serum
showed that B. pertussis-infection-induced serum antibodies were
cross reactive with B. bronchiseptica antigens (Figure 5). The size of
one of the cross-reactive bands at approximately 65-72 KDa
suggested that the band was pertactin, an antigenic protein known
to induce protective immunity [24,34,40]. Several other B.
bronchiseptica antigens appeared to be cross-reactive to B. pertussis-
infection-induced serum. There was little to no recognition of these
lysates when probed with naı ¨ve serum at the same dilution.
Immunization with B. pertussis-derived antigens is
protective against B. bronchiseptica challenge
Since pertactin and filamentous hemagglutinin are expressed by
both B. pertussis and B. bronchiseptica and are included in some
current acellular vaccines, we went on to determine if immunity to
pertactin or filamentous hemagglutinin contributed to B. pertussis-
induced immunity to B. bronchiseptica. Wild type mice were
immunized with purified B. pertussis-derived pertactin, filamentous
hemagglutinin, or aP vaccine, which contains these two shared
antigens. These mice were then challenged with B. pertussis or B.
bronchiseptica and dissected 3 days later to quantify bacterial
numbers. Immunization reduced numbers of B. pertussis by.99%,
relative to adjuvant-treated mice, (Figure 6A, B and C), consistent
with previous findings [34]. Immunization with these B. pertussis
antigens reduced B. bronchiseptica numbers by.90% in the trachea
and lungs, as compared to numbers in adjuvant-treated mice
(Figure 6). These data indicate that immunization with B. pertussis-
derived antigens induces an immune response which protects the
trachea and lungs of mice against either B. pertussis or B.
bronchiseptica infection.
B. pertussis-induced immunity protects against human
isolates of B. bronchiseptica
To determine if B. pertussis-induced immunity is sufficient to
protect against recent human clinical isolates of B. bronchiseptica,
wild type mice were immunized with B. pertussis and challenged
with two B. bronchiseptica Complex IV isolates [5], strain M0149
and strain 345. These strains, which are divergent from the
prototypical B. bronchiseptica Complex I strain, RB50, are more
closely related to B. pertussis and are both from human-associated
lineages [5]. Since the normal 5610
5 CFU dose was lethal to naı ¨ve
mice, strain 345 was delivered in inocula of 2610
5 CFU. These
bacteria grew to 10
6 in the lungs and 10
5 in the trachea of naı ¨ve
mice (Figure 7). In contrast, B. pertussis-immunization reduced the
Figure 4. Clearance of B. bronchiseptica from the LRT in B.
pertussis-immunized C3
2/2 and FccR
2/2 mice. Naı ¨ve (black bars),
B. pertussis-vaccinated (white bars), or B. pertussis-convalescent
(hatched bars) mice were dissected Day 3 post gentimicin
R B.
bronchiseptica inoculation. Bacterial numbers in the (A) trachea and
(B) lungs are represented as the mean Log10 CFU+/2SEM. Dashed line
indicates the lower limit of detection. * indicates statistical difference (P
value,0.05) between naı ¨ve and treated mouse. { indicates statistical
difference (P value,0.05) between mutant and similarly treated wild
type mice.
doi:10.1371/journal.pone.0006778.g004
Figure 5. Analysis of cross-reacting antigens between B.
pertussis and B. bronchiseptica. Lysates of B. pertussis (B.p.)o rB.
bronchiseptica (B.b.) were loaded in the indicated wells and separated
by SDS-PAGE gel. Proteins were transferred to PVDF membrane, and
then probed with naı ¨ve serum or B. pertussis-infection induced immune
serum (B.p. IS).
doi:10.1371/journal.pone.0006778.g005
Bordetella Cross Immunity
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(Figure 7A and B) by Day 3 post-challenge; indicating that
immunity to B. pertussis is sufficient to control B. bronchiseptica strains
recently isolated from humans.
Discussion
B. parapertussis avoids B.pertussis-induced immunity, a critical aspect
of its ability to transmit efficientlyto be successful in largely B.pertussis-
immune human populations [19,41–47] (X. Zhang, M. E.
Rodrı ´guez, E. T. Harvill, unpublished data). Although many B.
bronchiseptica lineages have broad host ranges, infect large proportions
of the animals in greatest contact with humans [3,4], and are known
to spillover from their animal hosts to humans [12], B. bronchiseptica
strains are not observed to transmit amongst humans. Based on these
observations we explored the possibility that B. bronchiseptica may be
limited in its ability to infect humans because it cannot avoid B.
pertussis-induced immunity. If B. bronchiseptica cannot avoid B. pertussis-
induced immunity, then well-established ecological theory predicts
that it cannot coexist with the human pathogen, explaining many of
the observations described above.
Immunity induced by B. pertussis infection or vaccination
significantly reduced B. bronchiseptica numbers in the LRT of mice
(Figure 1). Although the mechanism of protection in the trachea
and lungs appeared to be substantially similar, the major mucosal
antibody, IgA, was not required for B. pertussis-induced protection
against B. bronchiseptica in the lungs, but was important in the
trachea (Figure 2). This is consistent with our recent observations
that IgA is required for efficient control of B. bronchiseptica in the
trachea but not the lungs [48]. Immune serum recognized B.
bronchiseptica antigens and mediated protection that was dependent
on complement and neutrophils, but immunization-induced
immunity did not appear to require either complement or FccRs
(Figures 3, 4, and 5). Immunization with purified pertactin or
filamentous hemagglutinin derived from B. pertussis also conferred
protection against B. bronchiseptica (Figure 6). Together, these data
indicate that B. pertussis-induced immunity provides protection
against B. bronchiseptica in the LRT of mice.
Figure 6. Effect of vaccination with B. pertussis-derived antigens
on B. bronchiseptica colonization in the LRT. Groups of 3–4 C57BL/
6 mice were vaccinated with (A) 40 mg PRN, (B) 5 mg FHA or (C) 0.5 mL
of 1:5 dilution of Adacel in PBS and Imject Alum on Days 0 and 14.
Adjuvant-only control (white bars) and protein with adjuvant (black
bars) vaccinated mice were challenged on Day 28 with B. pertussis (B. p.)
or B. bronchiseptica (B. b.) and dissected Day 3 post-challenge. Bacterial
numbers are represented as the mean Log10 CFU+/2SEM. Dashed line
indicates the lower limit of detection. * indicates statistical difference (P
value of ,0.05) between adjuvant only and protein with adjuvant
treated groups.
doi:10.1371/journal.pone.0006778.g006
Figure 7. Human isolated, Complex IV B. bronchiseptica
colonization of B. pertussis-immune mice. Groups of 4 naı ¨ve (black
bars), B. pertussis-vaccinated (white bars) or B. pertussis-convalescent
(hatched bars) C57BL/6 mice were challenged with B. bronchiseptica
strain (A) M0149 or (B) 345 and dissected Day 3 post-challenge. Bacterial
numbers are represented as the mean Log10 CFU+/2SEM. Dashed line
indicates the lower limit of detection. * indicates statistical difference (P
value of ,0.05) between naı ¨ve and treated groups.
doi:10.1371/journal.pone.0006778.g007
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6778In developed countries, vaccination against B. pertussis begins at
a very early age. In certain populations, the seroprevalence of B.
pertussis-specific antibodies exceeds 90% [49]. If the ability to
colonize the LRT in large numbers and cause inflammation and
disease symptoms (coughing) are important to B. bronchiseptica
transmission, as they are to the other bordetellae, then these
measures of immunity to B. pertussis are likely to limit the
infectiousness of B. bronchiseptica in humans [17]. This ‘‘herd
immunity’’ would not protect individuals in whom immunity had
waned, or those that are immunodeficient, but the high prevalence
of B. pertussis-immunity in their surroundings would dampen
opportunities for transmission by decreasing the number of
susceptible individuals. This would explain why B. bronchiseptica
infections are generally associated with an animal source and why
chains of transmission are generally not established [12].
Furthermore, this theoretical framework also explains the
observed association of B. bronchiseptica disease in humans with
an immunocompromised state [7–12,50,51].
Our data show that B. pertussis immunity does not protect the
nasal cavities of mice from B. bronchiseptica colonization (Figure 1).
It is possible, and consistent with our model, that B. bronchiseptica
may be present in the nasal cavity of humans. However, it would
be hard to imagine how either the bacterium or its immunological
effects on B. pertussis epidemiology, and serological monitoring,
could go unnoticed. Extensive samplings of nasophayngeal swabs
and testing of serum reactivity that have revealed B. pertussis, B.
parapertussis and even B. holmesii have not revealed B. bronchiseptica
[3,12,42–44,52–55], even though it is easier to culture. Alterna-
tively, it is possible that the nasal cavity of humans is not conducive
to Bordetella infection, possibly due to differences in physiology,
immunology or other competitive flora. This could explain why B.
pertussis appears to have lost the ability to persist in the nasal cavity
of mice, while every B. bronchiseptica strain examined retains this
ability [23,56] (A.M. Buboltz, T.L. Nicholson, L.S. Weyrich, E.T.
Harvill, unpublished data). However, since human Bordetella
infections are highly contagious via the cough-induced respiratory
droplets, the ability of B. pertussis-induced immunity to limit B.
bronchiseptica to the nasal cavity should be sufficient to prevent its
efficient transmission.
There are likely to be multiple factors that limit the success of an
invading pathogen in a new host. Although spillover opportunity
and individual host specificity are often considered, more often
overlooked are the possible effects of resident flora on the success
of the invader. Our data show that immunity to B. pertussis can
have a substantial effect on B. bronchiseptica infection. Although a
high level of individual immunity may prevent many initial
infections or diseases, the variable immunity within human
populations is more likely to allow occasional infections while
having a more dramatic effect via ‘‘herd immunity’’ that inhibits
the establishment of a successful chain of transmission. This model
is consistent with much of the existing experimental and clinical
data, including sporadic infections often associated with an
immunocompromised state [8–10,12,50,51]. It also leads to the
prediction that B. bronchiseptica infections in humans may occur
much more commonly than are reported, and improved
surveillance may test this prediction. We can further predict that
changes in the B. pertussis vaccination- or infection-induced
immune status of human populations will affect the observed rate
of zoonotic B. bronchiseptica disease and, more importantly, their
opportunity to establish chains of infection to emerge as new
infectious agents.
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